Condition
Ebola Hemorrhagic Fever
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Completed3
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02911415CompletedPrimary
Open Study of the Duration of Immunity After Vaccination With GamEvac-Combi
NCT00374309Phase 1CompletedPrimary
Experimental Vaccine for Prevention of Ebola Virus Infection
NCT01593072Phase 1WithdrawnPrimary
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers
NCT01353027Phase 1CompletedPrimary
Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus
Showing all 4 trials